BUY Aurobindo Pharma — Ashish Kyal, Waves Strategy Advisors
byAshish Kyal, Waves Strategy AdvisorsHorizon: NA (inferred 1–3 months)29 Jul 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
3 advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days
Advisor consensus · adjacent horizon·29 Jul · 4d ago
Aurobindo Pharma has signed a non-exclusive voluntary license agreement with MSD to supply generic alimatravir to 129 Low- & Middle-Income Countries (LMICs). This royalty-free agreement aims to expand
BSE · Company Update·24 Jul · 1w ago
Aurobindo Pharma is acquiring majority ownership control in A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA, expanding its business.
BSE · Company Update·23 Jul · 1w ago
Aurobindo Pharma subsidiary gets Brazil regulator nod for Hyderabad biosimilars facility
NewsCnbc-Tv18·21 Jul · 2w ago
Aurobindo Pharma signs licensing pact with Merck to supply generic HIV drug in 129 countries
NewsCnbc-Tv18·24 Jul · 1w ago
Aurobindo Pharma arm Apitoria to acquire 80% stake in A1 Biochem Group for $17 million
NewsCnbc-Tv18·23 Jul · 1w ago
Aurobindo Pharma Limited has incorporated a new wholly owned stepdown subsidiary in Indonesia.
NSE · Acquisition·10 Jul · 3w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.